Pancreatic Cancer Research

ResearcherFirst Hospital of China Medical UniversityActive in the last 2 years

Xiujuan Qu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0005-9366-2314; OpenAlex author ID A5006455181. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
21
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 10

  1. NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial. Co-author DOI 10.1038/s41467-026-68409-0↗
  2. Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept. Last author DOI 10.1186/s13046-023-02935-3↗
  3. Correction: Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept. Last author DOI 10.1186/s13046-024-02953-9↗
  4. microRNA-569 inhibits tumor metastasis in pancreatic cancer by directly targeting NUSAP1. Co-author DOI 10.18632/aging.204035↗
  5. MicroRNA-29b-2-5p inhibits cell proliferation by directly targeting Cbl-b in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-018-4526-z↗
  6. DNA methyltransferase 3a modulates chemosensitivity to gemcitabine and oxaliplatin via CHK1 and AKT in p53‑deficient pancreatic cancer cells. Co-author DOI 10.3892/mmr.2017.7923↗
  7. Cbl-b predicts postoperative survival in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.18714↗
  8. MicroRNA-891b is an independent prognostic factor of pancreatic cancer by targeting Cbl-b to suppress the growth of pancreatic cancer cells. Last author DOI 10.18632/oncotarget.11001↗
  9. Serum calcium level used as a prognostic predictor in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.clinre.2014.01.012↗
  10. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study. Last author DOI 10.1186/1477-7819-12-171↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wenyu Luo · 2 shared papers, 2024 · strength 0.72
  2. Xiaofang Che · 5 shared papers, 2016–2022 · strength 0.47
  3. Ce Li · 4 shared papers, 2016–2022 · strength 0.38
  4. Xianghong Yang · 3 shared papers, 2016–2018 · strength 0.22
  5. Qian Dong · 4 shared papers, 2014–2017 · strength 0.21
  6. Yanqiao Zhang · 1 shared paper, 2026 · strength 0.19
  7. Xiuchao Wang · 1 shared paper, 2026 · strength 0.19
  8. Song Gao · 1 shared paper, 2026 · strength 0.19
  9. Chuntao Gao · 1 shared paper, 2026 · strength 0.19
  10. Tiansuo Zhao · 1 shared paper, 2026 · strength 0.19
  11. Chengyou Du · 1 shared paper, 2026 · strength 0.19
  12. Zhihua Li · 1 shared paper, 2026 · strength 0.19
  13. Jihui Hao · 1 shared paper, 2026 · strength 0.19
  14. Rui Liu · 1 shared paper, 2026 · strength 0.19
  15. Xianglin Yuan · 1 shared paper, 2026 · strength 0.19
  16. Xiaohui Guo · 1 shared paper, 2022 · strength 0.19
  17. Wei Jing · 3 shared papers, 2014–2018 · strength 0.18
  18. Zhi Li · 2 shared papers, 2014–2017 · strength 0.11
  19. Yao Zhang · 2 shared papers, 2014 · strength 0.09
  20. Na Song · 1 shared paper, 2018 · strength 0.09
  21. Yunpeng Liu · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.